These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30873741)

  • 1. Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.
    Crauwels HM; Osiyemi O; Zorrilla C; Bicer C; Brown K
    HIV Med; 2019 May; 20(5):337-343. PubMed ID: 30873741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.
    Crauwels HM; Kakuda TN; Ryan B; Zorrilla C; Osiyemi OO; Yasin S; Brown K; Verboven P; Hillewaert V; Baugh B
    HIV Med; 2016 Oct; 17(9):643-52. PubMed ID: 27187894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total and unbound darunavir pharmacokinetics in pregnant women infected with HIV-1: results of a study of darunavir/ritonavir 600/100 mg administered twice daily.
    Zorrilla CD; Wright R; Osiyemi OO; Yasin S; Baugh B; Brown K; Coate B; Verboven P; Mrus J; Falcon R; Kakuda TN
    HIV Med; 2014 Jan; 15(1):50-6. PubMed ID: 23731450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
    Moltó J; Curran A; Miranda C; Challenger E; Santos JR; Ribera E; Khoo S; Valle M; Clotet B
    J Antimicrob Chemother; 2018 Mar; 73(3):732-737. PubMed ID: 29237008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.
    Momper JD; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Badell ML; Acosta EP; Purswani M; Smith E; Chakhtoura N; Park K; Burchett S; Shapiro DE; Mirochnick M;
    AIDS; 2018 Nov; 32(17):2507-2516. PubMed ID: 30134297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cobicistat-containing antiretroviral regimens are not recommended during pregnancy: viewpoint.
    Boyd SD; Sampson MR; Viswanathan P; Struble KA; Arya V; Sherwat AI
    AIDS; 2019 May; 33(6):1089-1093. PubMed ID: 30946163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Scott GB; Paul ME; Febo IL; Burchett S; Smith E; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Yang DZ; Capparelli EV; Mirochnick M; Best BM;
    AIDS; 2021 Jul; 35(8):1191-1199. PubMed ID: 34076612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of total and unbound darunavir in HIV-1-infected pregnant women.
    Colbers A; Moltó J; Ivanovic J; Kabeya K; Hawkins D; Gingelmaier A; Taylor G; Weizsäcker K; Sadiq ST; Van der Ende M; Giaquinto C; Burger D;
    J Antimicrob Chemother; 2015 Feb; 70(2):534-42. PubMed ID: 25326090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Darunavir/cobicistat once daily for the treatment of HIV.
    Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
    Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
    Elliot ER; Amara A; Pagani N; Else L; Moyle G; Schoolmeesters A; Higgs C; Khoo S; Boffito M
    J Antimicrob Chemother; 2017 Jul; 72(7):2035-2041. PubMed ID: 28407075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and Safety of Darunavir/Ritonavir in HIV-Infected Pregnant Women.
    Khoo S; Peytavin G; Burger D; Hill A; Brown K; Moecklinghoff C; La Porte C; Hadacek MB
    AIDS Rev; 2017; 19(1):16-23. PubMed ID: 28182610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
    Ramgopal M; Osiyemi O; Zorrilla C; Crauwels HM; Ryan R; Brown K; Hillewaert V; Baugh B
    J Acquir Immune Defic Syndr; 2016 Nov; 73(3):268-274. PubMed ID: 27159225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of dolutegravir with and without darunavir/cobicistat in healthy volunteers.
    Elliot ER; Cerrone M; Challenger E; Else L; Amara A; Bisdomini E; Khoo S; Owen A; Boffito M
    J Antimicrob Chemother; 2019 Jan; 74(1):149-156. PubMed ID: 30272231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
    Momper JD; Wang J; Stek A; Shapiro DE; Powis KM; Paul ME; Badell ML; Browning R; Chakhtoura N; Denson K; Rungruengthanakit K; George K; Capparelli EV; Mirochnick M; Best BM;
    J Acquir Immune Defic Syndr; 2022 Mar; 89(3):303-309. PubMed ID: 34732682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lowered Rilpivirine Exposure During the Third Trimester of Pregnancy in Human Immunodeficiency Virus Type 1-Infected Women.
    Schalkwijk S; Colbers A; Konopnicki D; Gingelmaier A; Lambert J; van der Ende M; Moltó J; Burger D;
    Clin Infect Dis; 2017 Oct; 65(8):1335-1341. PubMed ID: 28595298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Splitting or Crushing on the Relative Bioavailability of the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen.
    Brown K; Thomas D; McKenney K; Reeder M; Simonson RB; Bicer C; Nettles RE; Crauwels H
    Clin Pharmacol Drug Dev; 2019 May; 8(4):541-548. PubMed ID: 30508308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of Once Versus Twice Daily Darunavir in Pregnant HIV-Infected Women.
    Stek A; Best BM; Wang J; Capparelli EV; Burchett SK; Kreitchmann R; Rungruengthanakit K; Cressey TR; Mofenson LM; Smith E; Shapiro D; Mirochnick M
    J Acquir Immune Defic Syndr; 2015 Sep; 70(1):33-41. PubMed ID: 25950206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.
    Lê MP; Chaix ML; Chevret S; Bertrand J; Raffi F; Gallien S; El Abbassi EMB; Katlama C; Delobel P; Yazdanpanah Y; Saillard J; Molina JM; Peytavin G;
    J Antimicrob Chemother; 2018 Aug; 73(8):2120-2128. PubMed ID: 29905808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.